Discover what's new.

Access the latest news, business developments, company updates, industry trends, events and more.

| By Kelley Gipson

Computation, COVID diagnosis advance at UConn

Neag School assistant professor of learning sciences, Ido Davidesco, has received a $1.4 million grant from the National Science Foundation to develop a month-long computational...

| By Kelley Gipson

Yale takes new approach to breeding microbiomes

The question of whether groups of organisms respond to evolution as a collective — through so called multi-level selection — has been studied for decades,...

| By Kelley Gipson

Cybrexa appoints Stephen Basso CFO

Cybrexa Therapeutics has appointed pharmaceutical and financial services veteran Stephen Basso as Chief Financial Officer. “With our lead therapeutic candidate, CBX-12, currently in its Phase 1...

| By Kelley Gipson

Alexion co-founder raises $40M for Gennao Bio

A gene therapy biotech helmed by an Alexion Pharmaceuticals co-founder has raised $40 million to develop a pipeline of drugs based on technology it licensed...

| By Kelley Gipson

Couture joins CytoVeris as Director of Quality

CytoVeris reports that Henry Couture has joined the company as Director of Quality. Mr. Couture has an extensive background with over 20 years of experience leading...

| By Kelley Gipson

Osmol initiates IND studies re neuropathy

Osmol Therapeutics reports it has initiated Investigational New Drug (IND) enabling studies to develop a therapy to prevent chemotherapy-induced peripheral neuropathy (CIPN). A phase 1...

| By Kelley Gipson

Yale and BI seek applications from postdocs

Yale University and Boehringer Ingelheimare seeking applications for Postdoctoral Researchers for a newly launched Biomedical Data Science Fellowship, which is a three-year full-time program. Applicants...

| By Kelley Gipson

Cybrexa doses first patient in Phase 1/2 trial

Cybrexa Therapeutics reports that the first patient has been dosed in a Phase 1/2 clinical trial evaluating CBX-12 (alphalex™-exatecan), the company’s lead therapeutic candidate. The...